Cost-utility of initial medical management for Crohn’s disease perianal fistulae

Kristen O. Arseneau, Steven Cohn, Fabio Cominelli, Alfred F. Connors

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Background and Aims: The cost-utility of infliximab is unknown. The aim of this study was to determine the incremental cost-utility (CUinc) of medical therapy for Crohn's disease (CD) perianal fistula. Methods: A Markov model was used to simulate a 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with episodic reinfusion (intervention II), and 6MP/met + infliximab as second-line therapy (intervention III). Utilities were elicited from patients with CD and healthy individuals by standard gamble, and costs were obtained from hospital billing data. Uncertainty was assessed by sensitivity analysis. Results: All strategies had similar effectiveness. Interventions I, II, and III were slightly more effective, but also more costly than 6MP/met (Intervention I: CUinc = $355,450/quality-adjusted life-years [QALY]; Intervention II: CUinc = $360,900/QALY; Intervention III: CUinc = $377,000/QALY). If the cost of infliximab were reduced to $304 per infusion, the CUinc for intervention II would be $54,050/QALY. Conclusions: Based on available data, all strategies had similar effectiveness in our model, but infliximab was much more expensive than 6MP/met. The incremental benefit of infliximab for treating CD perianal fistulae over a 1-year period may not justify the higher cost. Prospective studies directly comparing 6MP/met and infliximab are warranted.

Original languageEnglish (US)
Pages (from-to)1640-1656
Number of pages17
JournalGastroenterology
Volume120
Issue number7
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Crohn Disease
6-Mercaptopurine
Fistula
Metronidazole
Costs and Cost Analysis
Quality-Adjusted Life Years
Infliximab
Therapeutics
Uncertainty
Prospective Studies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Cost-utility of initial medical management for Crohn’s disease perianal fistulae. / Arseneau, Kristen O.; Cohn, Steven; Cominelli, Fabio; Connors, Alfred F.

In: Gastroenterology, Vol. 120, No. 7, 01.01.2001, p. 1640-1656.

Research output: Contribution to journalArticle

Arseneau, Kristen O. ; Cohn, Steven ; Cominelli, Fabio ; Connors, Alfred F. / Cost-utility of initial medical management for Crohn’s disease perianal fistulae. In: Gastroenterology. 2001 ; Vol. 120, No. 7. pp. 1640-1656.
@article{da42cacd01af4c65816a289f1c896c56,
title = "Cost-utility of initial medical management for Crohn’s disease perianal fistulae",
abstract = "Background and Aims: The cost-utility of infliximab is unknown. The aim of this study was to determine the incremental cost-utility (CUinc) of medical therapy for Crohn's disease (CD) perianal fistula. Methods: A Markov model was used to simulate a 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with episodic reinfusion (intervention II), and 6MP/met + infliximab as second-line therapy (intervention III). Utilities were elicited from patients with CD and healthy individuals by standard gamble, and costs were obtained from hospital billing data. Uncertainty was assessed by sensitivity analysis. Results: All strategies had similar effectiveness. Interventions I, II, and III were slightly more effective, but also more costly than 6MP/met (Intervention I: CUinc = $355,450/quality-adjusted life-years [QALY]; Intervention II: CUinc = $360,900/QALY; Intervention III: CUinc = $377,000/QALY). If the cost of infliximab were reduced to $304 per infusion, the CUinc for intervention II would be $54,050/QALY. Conclusions: Based on available data, all strategies had similar effectiveness in our model, but infliximab was much more expensive than 6MP/met. The incremental benefit of infliximab for treating CD perianal fistulae over a 1-year period may not justify the higher cost. Prospective studies directly comparing 6MP/met and infliximab are warranted.",
author = "Arseneau, {Kristen O.} and Steven Cohn and Fabio Cominelli and Connors, {Alfred F.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/gast.2001.24884",
language = "English (US)",
volume = "120",
pages = "1640--1656",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Cost-utility of initial medical management for Crohn’s disease perianal fistulae

AU - Arseneau, Kristen O.

AU - Cohn, Steven

AU - Cominelli, Fabio

AU - Connors, Alfred F.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background and Aims: The cost-utility of infliximab is unknown. The aim of this study was to determine the incremental cost-utility (CUinc) of medical therapy for Crohn's disease (CD) perianal fistula. Methods: A Markov model was used to simulate a 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with episodic reinfusion (intervention II), and 6MP/met + infliximab as second-line therapy (intervention III). Utilities were elicited from patients with CD and healthy individuals by standard gamble, and costs were obtained from hospital billing data. Uncertainty was assessed by sensitivity analysis. Results: All strategies had similar effectiveness. Interventions I, II, and III were slightly more effective, but also more costly than 6MP/met (Intervention I: CUinc = $355,450/quality-adjusted life-years [QALY]; Intervention II: CUinc = $360,900/QALY; Intervention III: CUinc = $377,000/QALY). If the cost of infliximab were reduced to $304 per infusion, the CUinc for intervention II would be $54,050/QALY. Conclusions: Based on available data, all strategies had similar effectiveness in our model, but infliximab was much more expensive than 6MP/met. The incremental benefit of infliximab for treating CD perianal fistulae over a 1-year period may not justify the higher cost. Prospective studies directly comparing 6MP/met and infliximab are warranted.

AB - Background and Aims: The cost-utility of infliximab is unknown. The aim of this study was to determine the incremental cost-utility (CUinc) of medical therapy for Crohn's disease (CD) perianal fistula. Methods: A Markov model was used to simulate a 1-year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with episodic reinfusion (intervention II), and 6MP/met + infliximab as second-line therapy (intervention III). Utilities were elicited from patients with CD and healthy individuals by standard gamble, and costs were obtained from hospital billing data. Uncertainty was assessed by sensitivity analysis. Results: All strategies had similar effectiveness. Interventions I, II, and III were slightly more effective, but also more costly than 6MP/met (Intervention I: CUinc = $355,450/quality-adjusted life-years [QALY]; Intervention II: CUinc = $360,900/QALY; Intervention III: CUinc = $377,000/QALY). If the cost of infliximab were reduced to $304 per infusion, the CUinc for intervention II would be $54,050/QALY. Conclusions: Based on available data, all strategies had similar effectiveness in our model, but infliximab was much more expensive than 6MP/met. The incremental benefit of infliximab for treating CD perianal fistulae over a 1-year period may not justify the higher cost. Prospective studies directly comparing 6MP/met and infliximab are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0035010383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035010383&partnerID=8YFLogxK

U2 - 10.1053/gast.2001.24884

DO - 10.1053/gast.2001.24884

M3 - Article

VL - 120

SP - 1640

EP - 1656

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -